AI-powered digital pathology firm PathAI has announced new partnerships with AI pathology innovators Mindpeak, Stratipath, and Primaa. Artificial intelligence products from the three firms will soon be available via PathAI's AISight Dx image management system.
This strategic expansion underscores PathAI’s commitment to delivering validated digital pathology workflows in Europe; further reinforcing its commitment to offering the most versatile, reliable, and interoperable image management system (IMS) on the market.
- Mindpeak’s 11 CE-IVD-marked AI portfolio spans breast cancer (HER2, ER, PR, Ki-67) and lung PD-L1, complemented by RUO assays for prostate and other tumour types - all accessible through PathAI’s platform to enable standardised biomarker quantification.
- Stratipath provides the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides.
- Primaa, specialising in AI-guided tools for dermatopathology and breast pathology, now delivers seamless integration into AISight Dx for high-throughput diagnostic accuracy.
“With these partnerships, PathAI continues to build the most comprehensive CE-IVD digital pathology ecosystem,” said Andy Beck MD PhD, Co-founder and CEO of PathAI. “Our expanded AI portfolio now including Mindpeak, Stratipath, and Primaa brings validated algorithms directly into the hands of pathologists via AISight Dx, accelerating adoption and reinforcing trust in digital workflows.”
Through AISight Dx, pathologists will benefit from: AI-powered overlays and CE-IVD algorithm results, embedded directly into diagnostic case review workflows; seamless integration with laboratory and hospital IT systems via AISight Link - a secure, open API; as well as a clinically endorsed algorithm catalogue, including tools for biomarker quantification, tissue classification, and diagnostic decision support.
AISight Dx is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland and FDA-cleared for primary diagnosis in the US.